[1] D'Apolito M,Marrone A,Servedio V,et al. Seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia. Haematologica,2007,92:133-134.
[2] Ostanek B,Furlan D,Mavec T,et al.UGT1A1（TA）n promoter polymorphism—a new case of a（TA）8 allele in Caucasians. Blood Cells Mol Dis,2007,38:78-82.
[3] Teng HC,Huang MJ,Tang KS,et al.Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults. Clin Genet,2007,72:321-328.
[4] Sampietro M,Lupica L,Perrero L,et al. TATA-box promoter mutant in the promoter of UDP-glucuronosyltransferase gene in Italian patients with Gilbert's syndrome. Ital J Gastroenterol,1998,30:194-198.
[5] Clarke DJ,Moghrabi N,Monaghan G,et al. Genetic defects of the UDP-glucuronosyltransferase-1（UGT1） gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin Chim Acta,1997,299:63-74.
[6] Jansen PL1,Bosma PJ,Bakker C,et al. Persistent unconjugated hyperbilirubinemia after liver transplantation due to an abnormal bilirubin UDP-glucuronosyl-transferase gene promotor sequence in the donor.J Hepatol,1997,27:1-5.
[7] Deinski HS,Lee CS, Dhillen AP, et al. UDP-glucUronosyltransferase in Gilbert's syndrome.Pathology,1996,28:238-241.
[8] Kleiner DE. Histopathological evaluation of drug-induced liver disease.Academic Press,2013:241-261.
[9] 中华医学会肝病学分会、消化病学分会、感染病学分会. 胆汁淤积性肝病诊断和治疗共识（2015）.实用肝脏病杂志,2016,19（6）：Ⅰ-ⅩⅠ.
[10] 中华医学会肝病学分会、消化病学分会、感染病学分会. 原发性硬化性胆管炎诊断和治疗专家共识（2015）.中华肝脏病杂志,2016,24（1）:14-22.
[11] Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics,2008,9（6）:703-715.
[12] 张玉喜,马晓瑞,马国仁. Gilbert综合征21例临床分析.宁夏医学杂志,2010,32：634-635.
[13] 孙艳玲,赵景民,辛绍杰,等.几种主要的先天性胆红素代谢障碍性肝病的临床及病理研究.中华传染病信息,2008,21（5）:287-290.
[14] 彭向欣,王泰龄.16例Gilbert综合征患者的临床、病理特征和基因分析.中华肝脏病杂志,2008,16（5）:372-374. |
